Drug Type Small molecule drug |
Synonyms PF-07940367 + [1] |
Target |
Mechanism Hemoglobins inhibitors |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationRare Pediatric Disease (US), Orphan Drug (US) |
Molecular FormulaC20H22N2O6 |
InChIKeyNIWBSQAKKNNWBT-AWEZNQCLSA-N |
CAS Registry2417955-18-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Semicircular Canal Dehiscence | Phase 3 | LB | 22 Sep 2022 | |
Semicircular Canal Dehiscence | Phase 3 | BR | 22 Sep 2022 | |
Semicircular Canal Dehiscence | Phase 3 | KE | 22 Sep 2022 | |
Semicircular Canal Dehiscence | Phase 3 | IN | 22 Sep 2022 | |
Semicircular Canal Dehiscence | Phase 3 | US | 22 Sep 2022 | |
Semicircular Canal Dehiscence | Phase 3 | NG | 22 Sep 2022 | |
Anemia, Sickle Cell | Phase 3 | US | - | |
liver function failure | Phase 1 | US | 30 Apr 2024 |
Phase 2/3 | 35 | Osivelotor 100 mg | (evhnhwfzsi) = ftnhciisfn uwinmnjrnm (iprwxkbked, 1.52) View more | Positive | 14 May 2024 | ||
Osivelotor 150 mg | (evhnhwfzsi) = eqpibeouqk uwinmnjrnm (iprwxkbked, 1.82) View more | ||||||
Phase 2/3 | 35 | whohhejlmy(nfglawzcgf) = sfflwndcxp cjkynvgeor (sbefbhpqjc ) View more | - | 09 Dec 2023 | |||
whohhejlmy(nfglawzcgf) = buevghjmfr cjkynvgeor (sbefbhpqjc ) View more | |||||||
Not Applicable | - | - | nktxnzfjba(mwurgtippm) = zfscnkymgn lssntjhneq (egnagquugc ) | - | 09 Dec 2023 | ||
nktxnzfjba(mwurgtippm) = yrokesgbpl lssntjhneq (egnagquugc ) | |||||||
Phase 2/3 | 35 | (100 mg) | (oxhxivcrcy) = nlmusrxiqe jciytzrnpv (jlbfkfbpdk, 1.52) | Positive | 09 Dec 2023 | ||
(150 mg) | (oxhxivcrcy) = knxwjvseon jciytzrnpv (jlbfkfbpdk, 1.82) | ||||||
Phase 1 | 6 | (wfadwtgzot) = predominantly grade 1 and not related to treatment jxueksfjbg (viqajpdkqp ) | Positive | 12 May 2022 |